MedTrace Logo

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

NCT00102687 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2019-11-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if azacitidine, combined with Best Supportive Care (BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a different doses and dosing schedules.

Conditions

Interventions

DRUG

azacitidine

Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • CL Beach · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-01
Primary Completion
2008-08-01
Completion
2008-08-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00102687 on ClinicalTrials.gov